U.S. Markets closed

Amarantus BioScience Holdings, Inc. (AMBS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0119+0.0014 (+12.86%)
At close: 3:53PM EDT

Amarantus BioScience Holdings, Inc.

45 Wall Street
Suite 920
New York, NY 10005
United States
650-862-5391
http://www.amarantus.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gerald E. CommissiongCEO, Pres & DirectorN/AN/A1983
Dr. John Wesley CommissiongChief Scientific Officer, Director & Member of Scientific Advisory BoardN/AN/A1945
Mr. Robert Lewis HarrisCompliance Officer & DirectorN/AN/A1944
Dr. Elise BrownellSr. VP of Operations & Project ManagementN/AN/AN/A
Aimee BoutcherDirector of Investor RelationsN/AN/AN/A
Dr. Ravi KironSr. VP of Bus. Devel.N/AN/A1960
Dr. Paula T. TrzepaczChief Medical Advisor to Elto Pharma and Breakthrough DiagnosticsN/AN/AN/A
Dr. Brian E. HarveyChief Regulatory Advisor & Member of Board of AdvisorsN/AN/AN/A
Dr. Richard Kagan M.D.Chief Medical Advisor to Cutanogen Corp.N/AN/AN/A
Dr. Owen GarrickCorp. AdvisorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Corporate Governance

Amarantus BioScience Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.